美国提高新药审评效率的审评模式改进与思考

中国药物警戒 ›› 2015, Vol. 12 ›› Issue (8): 471-475.

美国提高新药审评效率的审评模式改进与思考

高婧, 杨悦

沈阳药科大学工商管理学院,辽宁沈阳 110016

收稿日期:2015-09-02 修回日期:2015-09-02 出版日期:2015-08-08 发布日期:2015-09-02
通讯作者: 杨悦,女,博士,教授·博导,药事法规与药品政策。E-mail:yyue315@126.com
作者简介:高婧,女,在读硕士,药事管理。

Improvement and Discussion of Review Model for New Drugs in America

GAO Jing, YANG Yue

School of Business Administration, Shenyang Pharmaceutical University, Liaoning Shenyang 110016, China

Received:2015-09-02 Revised:2015-09-02 Online:2015-08-08 Published:2015-09-02

摘要/Abstract

摘要： 目的为完善我国新药审评模式提供参考。方法通过介绍PDUFAV中美国FDA对新分子实体和创新生物制品审评模式的改进,并对实施两年来的效果进行分析,探索其加强沟通、提高审评透明度和首轮通过率的方法,提出几点思考。结果新审评模式合理调整了审评时限,为申请者和审评者提供了充足的时间补充和审评申请材料,里程碑会议的有序召开为双方提供了双向沟通的机会,第三方的评估结果显示,新审评模式有效推进了审评进程,提高了审评透明度和首轮审评通过率,增加了审评的可预见性,尤其对特殊审评药物产生了明显的积极影响。结论对新药审评模式的设计应考虑在保障充足审评资源的前提下,对审评的关键节点加以控制,设置合理审评期限,通过加强申请者和审评者间的沟通提高首轮审评效率和效果。

关键词: PDUFAV, 新药审评模式

Abstract: Objective To provide references for Chinese review model for new drugs. Methods Improved review model for NMENDAs and Original BLAs in PDUFAV was briefly introduced, assessed and analyzed. We explored the way of enhancing communication, review transparency and first-cycle approval rate and some revelations were put forward. Results The new review model adjusts PDUFA review timelimit and gives applicants and review teams enough time to improve and review applications respectively. Milestone meetings offer two-way communication opportunities for them. The third-party assessment shows that new review model promoted review process, improved review transparency and first-cycle approval rates and the review process is more predictable, especially for applications with special designations, such as Breakthrough Therapy and Fast Track. Conclusion When considering new drug review model, we should guarantee adequate review resources, control key review steps and enhance communication between applications and reviewers to improve the efficiency and effectiveness of first-cycle review.

Key words: PDUFAV, new drug review model

中图分类号:

高婧, 杨悦. 美国提高新药审评效率的审评模式改进与思考[J]. 中国药物警戒, 2015, 12(8): 471-475.

GAO Jing, YANG Yue. Improvement and Discussion of Review Model for New Drugs in America[J]. Chinese Journal of Pharmacovigilance, 2015, 12(8): 471-475.

参考文献

[1] Cantor D J. Prescription Drug User Fee Act of 1992: Effects On Bringing New Drugs To Market[C]. Congressional Research Service, Library of Congress, 1997：97-838E.
[2] John K. Jenkins. CDER New Drug Review: 2014 Update[EB/OL]. (2014-12-11) [2015-06-05]. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacOf/CDER/UCM426549.pdf.
[3] FDA.Assessment of the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications in Prescri-ption Drug User Fee Act V; Request for Comments[J]. Federal Register, 2012, 77(130): 40072-40073.
[4] Judit Milstein. 21st Century Review[EB/OL].(2013-07-19)[2015-06-07].http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM361324.pdf.
[5] Eastern Research Group, Inc. Assessment of the Program for Enhanced Review Transparency and Communication for NMENDAs and Original BLAs in PDUFA V Interim Report: Fiscal Years 2013-2014[EB/OL].(2015-03-27)[2015-06-15].http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM436448.pdf.
[6] 王建英. 美国药品申报与法规管理[M].北京：中国医药科技出版 2005：29,147.
[7] CDER. WORLD OF CDER ADVISORY COMMITTEE PROCESS MODULE[EB/OL].[2015-07-04].http://www.accessdata.fda.gov/scripts/cderworld/index.cfm?action=advisorycommitteeprocess:main&unit=1&lesson=1&topic=5&page=1.
[8] 张象麟,刘璐,叶祖光. 简介美国药品专家咨询委员会及我国药品专家审评委员会[J].中国新药杂志,2013,12(10):789-791.
[9] FDA. Membership Types[EB/OL].(2015-05-20)[2015-07-04].http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/CommitteeMembership/MembershipTypes/default.htm.

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	马美英, 赵晓佩, 张梦瑶, 胡一琳. 我国药品追溯码编码制度研究探讨[J]. 中国药物警戒, 2024, 21(2): 167-172.
[3]	朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222.
[4]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[5]	马丽娜, 胡晓祯, 郑长辉, 孙颖, 赵旭, 曹俊岭, 肖小河. 基于“因毒为能”思想的有毒中药常山毒效转化知识图谱可视化分析[J]. 中国药物警戒, 2024, 21(1): 25-32.
[6]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[7]	田春华, 吴桂芝. 定期获益-风险评估报告在我国的实施思考[J]. 中国药物警戒, 2023, 20(12): 1382-1384.
[8]	赵燕, 李尧, 宋雅娜, 郑立佳, 李栋, 赵一飞, 卞蓉蓉, 董放. 警戒视域下开展医疗器械上市后主动监测的实践研究与思考[J]. 中国药物警戒, 2023, 20(12): 1385-1390.
[9]	逄瑜, 刘博, 吴文宇, 田月洁, 王涛. 英国患者报告制度建立的浅析与启示[J]. 中国药物警戒, 2023, 20(11): 1259-1263.
[10]	吴昀效, 于玥琳, 王胜锋, 孙凤, 孟若谷, 詹思延. 真实世界数据在疫苗上市后安全性主动监测中适用性评价分析[J]. 中国药物警戒, 2023, 20(10): 1081-1089.
[11]	贾晋生, 王青, 刘红亮, 侯永芳. 药品上市许可持有人药物警戒工作评估指标体系的探索[J]. 中国药物警戒, 2023, 20(10): 1090-1094.
[12]	刘红亮, 王青, 侯永芳. 基于真实世界数据老年常见病多重用药风险数据管理平台设计与实施[J]. 中国药物警戒, 2023, 20(10): 1095-1098.
[13]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.